Literature DB >> 16495270

Enterococcus gallinarum N04-0414 harbors a VanD-type vancomycin resistance operon and does not contain a D-alanine:D-alanine 2 (ddl2) gene.

David A Boyd1, Mark A Miller, Michael R Mulvey.   

Abstract

Enterococcus gallinarum N04-0414 (MIC for vancomycin, 256 microg/ml) harbored a vanD-type vancomycin resistance operon as well as the intrinsic vanC1 operon. The D-Ala:D-Ala ligase 2 gene (ddl2) was not present in the strain, though it is found downstream of the vanS gene from the vanC operon in E. gallinarum ATCC 49573 and 19 other E. gallinarum strains tested.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16495270      PMCID： PMC1426452          DOI： 10.1128/AAC.50.3.1067-1070.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  24 in total

1.  Characterization of a divergent vanD-type resistance element from the first glycopeptide-resistant strain of Enterococcus faecium isolated in Brazil.

Authors:  L M Dalla Costa; P E Reynolds; H A Souza; D C Souza; M F Palepou; N Woodford
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Molecular characterization of the vanD gene cluster and a novel insertion element in a vancomycin-resistant enterococcus isolated in Canada.

Authors:  D A Boyd; J Conly; H Dedier; G Peters; L Robertson; E Slater; M R Mulvey
Journal:  J Clin Microbiol       Date:  2000-06       Impact factor: 5.948

Review 3.  Genetics of glycopeptide resistance in gram-positive pathogens.

Authors:  Patrice Courvalin
Journal:  Int J Med Microbiol       Date:  2005-03       Impact factor: 3.473

Review 4.  Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci.

Authors:  N Woodford
Journal:  Microb Drug Resist       Date:  2001       Impact factor: 3.431

5.  Glycopeptide-resistant Enterococcus faecium BM4416 is a VanD-type strain with an impaired D-Alanine:D-Alanine ligase.

Authors:  B Perichon; B Casadewall; P Reynolds; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

6.  Transcriptional analysis of the vanC cluster from Enterococcus gallinarum strains with constitutive and inducible vancomycin resistance.

Authors:  Diana Panesso; Lorena Abadía-Patiño; Natasha Vanegas; Peter E Reynolds; Patrice Courvalin; Cesar A Arias
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

7.  Characterization of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339.

Authors:  B Casadewall; P Courvalin
Journal:  J Bacteriol       Date:  1999-06       Impact factor: 3.490

8.  vanC cluster of vancomycin-resistant Enterococcus gallinarum BM4174.

Authors:  C A Arias; P Courvalin; P E Reynolds
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

9.  A cluster of VanD vancomycin-resistant Enterococcus faecium: molecular characterization and clinical epidemiology.

Authors:  B E Ostrowsky; N C Clark; C Thauvin-Eliopoulos; L Venkataraman; M H Samore; F C Tenover; G M Eliopoulos; R C Moellering; H S Gold
Journal:  J Infect Dis       Date:  1999-10       Impact factor: 5.226

10.  Regulation of expression of the vanD glycopeptide resistance gene cluster from Enterococcus faecium BM4339.

Authors:  B Casadewall; P E Reynolds; P Courvalin
Journal:  J Bacteriol       Date:  2001-06       Impact factor: 3.490
View more
  2 in total

1.  vanD and vanG-like gene clusters in a Ruminococcus species isolated from human bowel flora.

Authors:  M-C Domingo; A Huletsky; R Giroux; F J Picard; M G Bergeron
Journal:  Antimicrob Agents Chemother       Date:  2007-08-27       Impact factor: 5.191

2.  New combinations of mutations in VanD-Type vancomycin-resistant Enterococcus faecium, Enterococcus faecalis, and Enterococcus avium strains.

Authors:  F Depardieu; M-L Foucault; J Bell; A Dubouix; M Guibert; J-P Lavigne; M Levast; P Courvalin
Journal:  Antimicrob Agents Chemother       Date:  2009-03-02       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.